PMID: 9435874Jan 22, 1998Paper

Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1

Cancer Immunology, Immunotherapy : CII
B J KroesenL F de Leij

Abstract

The bispecific monoclonal antibody (bsAb) BIS-1 combines a monoclonal-antibody(mAb)-defined specificity for the CD3 complex, as present on all T lymphocytes, with a mAb-defined specificity for the pancarcinoma/epithelium associated glycoprotein EGP-2. In vitro studies indicate that BIS-1 can direct T lymphocytes to kill EGP-2-positive tumour target cells. T cell pre-activation is necessary for this activity and can be obtained either via incubation of isolated peripheral blood mononuclear cells with CD3 mAb, followed by short culturing in recombinant interleukin-2-containing medium, or via costimulation with CD5- and CD28-based bsAb. Clinical application of BIS-1 was started in a pilot study in which carcinoma patients suffering from malignant ascites or intrapleural effusion were treated. In this study, ex vivo activated autologous lymphocytes were applied locally, i.e. intraperitoneally or intrapleurally, in the presence of BIS-1. Local inflammation and antitumour activity were observed, whereas no or only minor systemic toxicity was seen in these patients. Intravenous administration of BIS-1 F(ab')2 in combination with subcutaneously given recombinant interleukin-2 (i.v. bsAb/rIL-2 treatment) induced transient but considerab...Continue Reading

Citations

Sep 15, 2006·Journal of Immunotherapy·Christian EnsingerKurt W Schmid
Oct 13, 2015·Current Opinion in Hematology·Divaya Bhutani, Lawrence G Lum
Jul 10, 2004·Human Gene Therapy·Michele W L TengPhillip K Darcy
Nov 6, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alja J StelSebo Withoff
Sep 1, 2008·Expert Opinion on Drug Discovery·Lawrence G Lum, Zaid Al-Kadhimi
Nov 5, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Lawrence G Lum, Archana Thakur
Jan 21, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·G MolemaL F de Leij
Apr 18, 2014·Molecular Pharmaceutics·Haiming LuoWeibo Cai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.